INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Allergan Plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Allergan plc (NYSE: AGN) ("Allergan" or the "Company") securities during the period between February 25, 2014 and November 2, 2016, inclusive (the "Class Period"). Investors who wish to become proactively involved in the litigation have until January 3, 2017 to seek appointment as lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Allergan securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period that Allergan plc and Actavis plc were engaging and/or had engaged in conduct that would result in an antitrust investigation by the U.S. Department of Justice ("DOJ"), the DOJ investigation and the underlying conduct could cause prosecutors to file criminal charges for suspected price collusion, and between 2014-2015, the companies lacked effective internal controls over financial reporting. According to the complaint, following an August 6, 2016 filing and article announcing that the Company had received a subpoena from the DOJ relating to marketing and pricing, and a November 3, 2016 article revealing that prosecutors may file criminal charges, the value of Allergan shares declined significantly.